Metoprolol CR/XL in postmyocardial infarction patients with chronic heart failure: experiences from MERIT-HF

Jánosi, András; Ghali, Jalal K.; Herlitz, Johan; Czuriga, István; Klibaner, Michael; Wikstrand, John; Hjalmarson, Åke

doi:10.1016/s0002-8703(03)00163-7

Cited by 52 publications

(33 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[25][26][27] Clinical studies such as the Metoprolol Controlled-Release Randomized Intervention Trial in Heart Failure (MERIT-HF) have proved that ␤-blocker therapy in patients with HF not only can attenuate pathological remodeling of the heart but also may actually improve patient outcomes. 28,29 Therefore, preservation of S100A1-mediated positive inotropic effects under ␤-blocker treatment, as observed in this study, suggests potentially additive action of both strategies and supports a potential future clinical application of S100A1 gene therapy in HF, which could become safer with a cardioselective approach like that described here.…”

Section: Discussionsupporting

confidence: 81%

Stable Myocardial-Specific AAV6-S100A1 Gene Therapy Results in Chronic Functional Heart Failure Rescue

et al. 2007

View full text Add to dashboard Cite

Background-The incidence of heart failure is ever-growing, and it is urgent to develop improved treatments. An attractive approach is gene therapy; however, the clinical barrier has yet to be broken because of several issues, including the lack of an ideal vector supporting safe and long-term myocardial transgene expression. Methods and Results-Here, we show that the use of a recombinant adeno-associated viral (rAAV6) vector containing a novel cardiac-selective enhancer/promoter element can direct stable cardiac expression of a therapeutic transgene, the calcium (Ca 2ϩ )-sensing S100A1, in a rat model of heart failure. The chronic heart failure-rescuing properties of myocardial S100A1 expression, the result of improved sarcoplasmic reticulum Ca 2ϩ handling, included improved contractile function and left ventricular remodeling. Adding to the clinical relevance, long-term S100A1 therapy had unique and additive beneficial effects over ␤-adrenergic receptor blockade, a current pharmacological heart failure treatment.Conclusions-These findings demonstrate that stable increased expression of S100A1 in the failing heart can be used for long-term reversal of LV dysfunction and remodeling. Thus, long-term, cardiac-targeted rAAV6-S100A1 gene therapy may be of potential clinical utility in human heart failure.

show abstract

Section: Discussionsupporting

confidence: 81%

Stable Myocardial-Specific AAV6-S100A1 Gene Therapy Results in Chronic Functional Heart Failure Rescue

et al. 2007

View full text Add to dashboard Cite

show abstract

“…After treatment for 1 year, metoprolol succinate reduced total mortality by 40% and cardiac death/nonfatal acute MI by 45%. 88 …”

Section: ␤-Adrenergic-blocking Agentsmentioning

confidence: 99%

Navigating the Crossroads of Coronary Artery Disease and Heart Failure

et al. 2006

View full text Add to dashboard Cite

“…This has been demonstrated in two large trials published since 2000: the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) study showed a 23% risk reduction in all-cause mortality and reductions in CV mortality and non-fatal reinfarction, 111 and the Metoprolol CR/ XL Randomized Intervention Trial in Heart Failure (MERIT-HF) showed similar significant reductions in patients with severe LVSD postMI. 112 Compounding this effect is the advancement in beta-blocker development, with the more recent trials benefiting from the availability of thirdgeneration beta-blockers that provide vasodilatory effects independent of beta-blockade. 87 Another major difference is the time since MI, which would be expected to impact on mortality and HF progression.…”

Section: Exchangeabilitymentioning

confidence: 99%

A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure

McKenna

Burch²,

Suekarran³

et al. 2010

Health Technol Assess

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address. Paying by credit cardYou can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume. How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, from the public and consumer groups and from professional bodies ...

show abstract

Metoprolol CR/XL in postmyocardial infarction patients with chronic heart failure: experiences from MERIT-HF

Cited by 52 publications

References 20 publications

Stable Myocardial-Specific AAV6-S100A1 Gene Therapy Results in Chronic Functional Heart Failure Rescue

Stable Myocardial-Specific AAV6-S100A1 Gene Therapy Results in Chronic Functional Heart Failure Rescue

Navigating the Crossroads of Coronary Artery Disease and Heart Failure

A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure

Contact Info

Product

Resources

About